A pharma brand marketing company plans to raise Rs 11.02 crore via the BSE SME platform.
Goldline Pharmaceutical Ltd., a pharmaceutical products marketing company operating under the “Goldline” brand, opens for subscription on May 12 with the issue closing on May 14. The company is listing on the BSE SME platform through a fixed-price issue at Rs 43 per share.
What the Company Does
Goldline Pharmaceutical is a brand-and-distribution business in the pharmaceutical sector. Similar in structure to a pharma marketing company, it does not own any manufacturing facilities — the company’s operations are entirely focused on branding, procurement, and distribution of pharmaceutical products under the Goldline label, with all manufacturing outsourced to third-party contract manufacturers.
The pharma segment carries an additional regulatory dimension compared to other brand-and-distribution models — contract manufacturers must be compliant with GMP standards, drug controller norms, and other applicable regulations, meaning the company’s ability to operate is structurally dependent on the compliance posture of its suppliers.
At Rs 11.02 crore, this is one of the smaller IPOs in the current SME cycle. The post-IPO paid-up equity base is small, which indicates the company faces a longer gestation period before it would meet the eligibility criteria for mainboard migration.
Issue Details
| Particulars | Details |
|---|---|
| Issue Opens | May 12, 2026 |
| Issue Closes | May 14, 2026 |
| Listing | BSE SME (May 19, 2026) |
| Issue Price | Rs 43 per share (Fixed Price) |
| Face Value | Rs 10 |
| Issue Size | Rs 11.02 crore (100% Fresh Issue) |
| Lot Size | 3,000 shares (min 2 lots = 6,000 shares) |
| Min. Retail Investment | Rs 2,58,000 |
| BRLM | Cumulative Capital Pvt. Ltd. |
| Registrar | Bigshare Services Pvt. Ltd. |
BRLM Track Record: This is the 7th mandate from Cumulative Capital in the last three fiscals. All six prior listings recorded a premium on the date of listing, ranging from 4.35% to 37.5%.
Risks to Consider
The company is fully dependent on third-party manufacturers for its entire product range — in pharmaceuticals, any non-compliance by a contract manufacturer with regulatory standards could trigger product recalls, supply disruptions, or licence cancellations that directly affect the company’s ability to operate. The reported margins are notably higher than listed pharmaceutical marketing peers, which trade at P/E multiples of around 27.9x and 38.4x — a divergence that raises natural questions about margin sustainability and the quality of reported earnings. With a very small post-IPO equity base, post-listing liquidity in the stock could be very thin, making exits at desired prices difficult for investors.
Analyst View
Independent analysts flag the complete dependency on third-party supply as a major structural concern, alongside the margin profile that compares favourably — perhaps too favourably — to listed peers. The issue appears fully priced based on recent financial data. The small post-IPO paid-up equity base further extends the timeline to any potential mainboard migration.